Invitae Corporation filed SEC Form 8-K: Leadership Update

$NVTA
Medical Specialities
Health Care
Get the next $NVTA alert in real time by email
nvta-20231117
0001501134FALSE00015011342023-11-172023-11-17

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
 CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 17, 2023
invitaelogoa02.jpg
Invitae Corporation
(Exact name of the registrant as specified in its charter)
Delaware001-3684727-1701898
(State or other jurisdiction of(Commission(I.R.S. employer
incorporation or organization)File Number)identification number)
1400 16th Street, San Francisco, California 94103
(Address of principal executive offices, including zip code)
(415) 374-7782
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of exchange on which registered
Common Stock, $0.0001 par value per shareNVTANew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐



Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 17, 2023, Robert L. Nussbaum, MD, Chief Medical Officer of Invitae Corporation (the “Company”), notified the Company of his planned retirement, effective December 29, 2023. The Company extends its deepest gratitude to Dr. Nussbaum for his exceptional service and contributions to the Company’s success.




SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 17, 2023
 
INVITAE CORPORATION
By:
/s/ Thomas R. Brida
Name:Thomas R. Brida
Title:General Counsel


Get the next $NVTA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NVTA

DatePrice TargetRatingAnalyst
7/5/2023Underweight
JP Morgan
5/15/2023Mkt Perform → Underperform
Raymond James
1/31/2023$2.00Neutral → Sell
Goldman
8/25/2022$1.00Underperform
Credit Suisse
8/10/2022Neutral → Underweight
JP Morgan
7/26/2022$8.00 → $2.50Outperform → Market Perform
Cowen
7/21/2022Outperform → Mkt Perform
Raymond James
7/20/2022Buy → Neutral
Ladenburg Thalmann
More analyst ratings

$NVTA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Labcorp Announces Winning Bid for Select Assets of Invitae

    Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 BURLINGTON, N.C., April 24, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed, the court overseeing the process must issue an approval order following a hearing currently scheduled for May 6, 2024.

    $LH
    $NVTA
    Medical Specialities
    Health Care
  • Invitae Enters into Agreement with Labcorp for Sale of Business

    – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantially All of the Company's Assets, Ensuring Business Continuity for Customers, Partners and Employees – SAN FRANCISCO, April 24, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, announced that Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, has been selected as the winning bidder in the Company's auction in its sale process under Section 363 of the U.S. Bankruptcy Code. Labcorp will acquire substantially all of the Company's assets on a going concern basis

    $LH
    $NVTA
    Medical Specialities
    Health Care
  • Invitae Publishes its Environmental, Social and Governance (ESG) Report

    – Report details the company's commitment to improving healthcare through the power of genetic information and discloses Environmental, Social and Governance initiatives for fiscal year 2023 – SAN FRANCISCO, April 22, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, today published its 2024 Environmental, Social and Governance (ESG) Report. This report provides a holistic view of the company's approach to ESG and its performance and progress through measurable data and metrics during the 2023 fiscal year. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring c

    $NVTA
    Medical Specialities
    Health Care

$NVTA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$NVTA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$NVTA
Leadership Updates

Live Leadership Updates

See more
  • Aranscia Acquires YouScript from Invitae

    Pioneering Pharmacogenomics Platform Joins Portfolio of Complementary Precision Medicine Workflow Solutions Aranscia, a global provider of diagnostics software, services, and testing solutions, and Invitae Corporation, a leading medical genetics company, today announced that Aranscia has acquired select assets of the YouScript personalized medication management platform from Invitae Corporation in an all-cash transaction. YouScript is a widely recognized leader in providing actionable, real-time medication risk and pharmacogenomics (PGx) insights that enable healthcare providers and organizations to build, deliver, and scale comprehensive personalized medication management programs. YouSc

    $NVTA
    Medical Specialities
    Health Care
  • Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO

    SAN FRANCISCO, Sept. 25, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced the appointment of finance veteran Ana Schrank as the Company's chief financial officer (CFO), effective October 2. Robert Dickey, who has been the Company's interim CFO since August 2023, will transition to a consulting role for the Company and will work closely with Ms. Schrank and the leadership team to ensure a smooth transition.  www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the qu

    $NVTA
    Medical Specialities
    Health Care
  • Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer

    – Invitae adds chief commercial officer to leadership team; Innovative leader to help expand market share and drive revenue growth –  SAN FRANCISCO, Aug. 28, 2023  /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it has appointed Robert (Rob) Guigley as its chief commercial officer, effective September 5, 2023. Mr. Guigley brings to the role more than 20 years of commercial experience spanning biotechnology, pharmaceuticals, diagnostics and genetic testing. He will develop and implement Invitae's commercial strategy with a focus on driving profitable revenue growth, expanding the market, improving reimbursement levels and enhancing the service of

    $NVTA
    Medical Specialities
    Health Care

$NVTA
Financials

Live finance-specific insights

See more
  • Natera Acquires Reproductive Health Assets from Invitae

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE:NVTA), a leading medical genetics company, certain assets relating to Invitae's non-invasive prenatal screening and carrier screening business. Natera has made an upfront payment in the amount of $10 million to Invitae. In addition, the transaction includes $42.5 million in potential milestone payments including cash and litigation-related credits. Pursuant to the agreement, Invitae will transition its non-invasive prenatal screening and carrier screening customers to Natera. "We are committed to providing excellent service, and we look forward to the o

    $NTRA
    $NVTA
    Medical Specialities
    Health Care
  • Invitae Reports Second Quarter 2023 Financial Results

    – Reported revenue of $120.5 million, a 12% year-over-year decrease due to exited businesses and geographies; pro forma revenue up slightly year-over-year –  – GAAP gross margin was 27.4% and non-GAAP gross margin was 49.8%; continued improvement in non-GAAP gross margin for eight consecutive quarters – – Company improves ongoing cash burn annual guidance to $220-$245 million; adjusts 2023 revenue guidance to $480-$500 million from over $500 million previously – – Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time – SAN FRANCISCO, Aug. 8, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced financial and operating res

    $NVTA
    Medical Specialities
    Health Care
  • Invitae to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

    SAN FRANCISCO, July 26, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)">

    $NVTA
    Medical Specialities
    Health Care

$NVTA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more